Ashland (ASH) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.72%. A quarter ago, it was expected that this chemical company would post earnings of $0.21 per share when it actually produced earnings of $0.45, delivering a surprise of 114.29%.Over the last four quarters, the company ...

Exhibit 99.1 Ashland reports financial results1for second quarter fiscal 2024; issues outlook for third quarter and full-year fiscal 2024 • Sales of $575 million, down five percent from the prior-year quarter • Net income (including discontinued operations) of $120 million, or $2.39 per diluted share • Income from continuing operations of $121 million, or $2.40 per diluted share • Adjusted income from continuing operations excluding intangibles amortization expense of $64 million, or $1.27 per diluted share ...

WILMINGTON, Del., March 08, 2024 (GLOBE NEWSWIRE) -- In recognition of International Women's Day, Ashland Inc. (NYSE:ASH) is shining a spotlight on 30 inspirational female solvers from across the company to recognize their contributions, reinforce gender equity, drive parity, and help fuel inspiration for women in every corner of the world.  During the annual event, organized by the Ashland International Women's Network (AWIN), the company increased support for their ongoing partnership with greenlight4girl ...

Financial Data and Key Metrics Changes - Sales for the quarter ended December 31, 2023, were $473 million, a decline of 10% compared to the prior year [8][14] - Adjusted EBITDA decreased by 35% to $70 million, with an adjusted EBITDA margin of 14.8%, down from 20.6% in the prior year [15][9] - Adjusted EPS was $0.45, down from $0.97 in the prior year quarter [15] - Ongoing free cash flow improved to $66 million, up from a cash use of $21 million in the prior year [15][20] Business Line Data and Key Metrics Changes - Life Sciences sales declined by 3% to $200 million, with adjusted EBITDA decreasing by 8% to $48 million [16] - Personal Care sales decreased by 7% to $129 million, while adjusted EBITDA declined by 31% to $22 million [17] - Specialty Additives sales fell by 15% to $122 million, with adjusted EBITDA down 74% to $6 million [18] - Intermediates reported sales of $33 million, down 39% compared to the prior year, with adjusted EBITDA of $10 million [19] Market Data and Key Metrics Changes - Demand patterns improved throughout the quarter, with December sales exceeding expectations despite being seasonally lower [8][9] - Pricing in competitive segments turned modestly unfavorable compared to the prior year, impacting profitability [9] - Foreign currency had a favorable impact on sales of 1% [14] Company Strategy and Development Direction - The company is focused on executing, globalizing, innovating, and acquiring to build resilience and improve performance [11][31] - Portfolio optimization actions include divesting the nutraceuticals business and consolidating CMC production [21][22] - The company expects to complete portfolio optimization activities by the end of calendar year 2024 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improving demand trends, particularly in January and February [9][27] - The company anticipates sales in Q2 to be in the range of $565 million to $585 million, with adjusted EBITDA between $115 million and $125 million [29] - Key risks include demand recovery timing and variability in plant loading [29] Other Important Information - The company repurchased $100 million of shares during the quarter, with a total of $1.05 billion deployed over the last 30 months [11][20] - Cash on hand was approximately $440 million, with total available liquidity of roughly $1 billion [19] Q&A Session Summary Question: Can you describe the sequential strength in end markets and geographies? - Management noted broad-based improvements across segments, with December being stronger than expected and January continuing to strengthen [41] Question: Do you expect any impact from inventory control actions in Q2? - Management indicated they would maintain current inventory levels and not take significant inventory control actions throughout the year [43][47] Question: What is the expected EBITDA step-up into the second half? - Management clarified that they do not plan to build inventory and will produce to demand, expecting better absorption in the second half [49][51] Question: Can you provide details on the CMC production consolidation? - Management confirmed the closure of the CMC unit in Hopewell by the end of the quarter, with plans to repurpose assets in the future [60][62] Question: What is the outlook for variable compensation and merit increases? - Management expects a year-over-year increase of about $40 million in variable compensation and merit increases [65]

Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other c ...

PART I - FINANCIAL INFORMATION [Item 1. Financial Statements](index=3&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) For the quarter ended December 31, 2023, Ashland reported sales of $473 million, a 9.9% decrease year-over-year, and a net income of $26 million, down from $40 million in the prior-year period. The decline was primarily driven by lower sales volumes across most segments. Total assets slightly decreased to $5.87 billion from $5.94 billion at the end of the previous quarter. Cash flow from operations improved significantly to a $201 million inflow compared to a $29 million outflow in the same period last year, mainly due to better working capital management Consolidated Financial Performance (Q1 FY2024 vs Q1 FY2023) | Financial Metric | Three months ended Dec 31, 2023 | Three months ended Dec 31, 2022 | | :--- | :--- | :--- | | **Sales** | $473 million | $525 million | | **Gross Profit** | $98 million | $165 million | | **Operating Income (Loss)** | ($18 million) | $37 million | | **Net Income** | $26 million | $40 million | | **Diluted EPS** | $0.51 | $0.73 | Condensed Consolidated Balance Sheet Highlights | (In millions) | December 31, 2023 | September 30, 2023 | | :--- | :--- | :--- | | **Total Current Assets** | $1,365 | $1,506 | | **Total Assets** | $5,866 | $5,939 | | **Total Current Liabilities** | $414 | $456 | | **Long-term Debt** | $1,341 | $1,314 | | **Total Stockholders' Equity** | $3,053 | $3,097 | Consolidated Cash Flow Summary | (In millions) | Three months ended Dec 31, 2023 | Three months ended Dec 31, 2022 | | :--- | :--- | :--- | | **Cash from Operating Activities** | $201 | ($29) | | **Cash from Investing Activities** | ($26) | ($27) | | **Cash from Financing Activities** | ($139) | ($27) | | **Net Increase (Decrease) in Cash** | $23 | ($114) | [Note A – Significant Accounting Policies](index=6&type=section&id=NOTE%20A%20%E2%80%93%20SIGNIFICANT%20ACCOUNTING%20POLICIES) The financial statements are prepared in accordance with U.S. GAAP for interim reporting. They should be read in conjunction with the company's Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The company's reportable segments are Life Sciences, Personal Care, Specialty Additives, and Intermediates - Ashland's reportable segments are identified as Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Unallocated and Other category includes corporate governance and legacy matters[12](index=12&type=chunk) - The preparation of financial statements requires management to make significant estimates and assumptions, particularly for environmental remediation, asbestos litigation, goodwill, and income taxes[13](index=13&type=chunk) [Note B – Discontinued Operations](index=6&type=section&id=NOTE%20B%20%E2%80%93%20DISCONTINUED%20OPERATIONS) The company reported a loss from discontinued operations of $2 million for the quarter, consistent with the prior-year period. This loss is primarily related to adjustments from the divested Performance Adhesives business and ongoing asbestos-related litigation liabilities Loss from Discontinued Operations (Net of Tax) | (In millions) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Performance Adhesives | ($3) | ($1) | | Asbestos-related litigation | $1 | $0 | | Distribution | $0 | ($1) | | **Total** | **($2)** | **($2)** | [Note C – Restructuring Activities](index=7&type=section&id=NOTE%20C%20%E2%80%93%20RESTRUCTURING%20ACTIVITIES) Ashland incurred restructuring costs related to targeted organizational actions and plant optimization. In Q1 2024, this included $3 million in severance costs and $21 million in accelerated depreciation for a Specialty Additives manufacturing facility - As part of plant optimization, Ashland incurred **$21 million** of accelerated depreciation for a Specialty Additives manufacturing facility, recorded within cost of goods sold[23](index=23&type=chunk) - The company recorded **$3 million** in severance expense in Q1 2024 as part of ongoing restructuring actions that began in fiscal 2023. The severance reserve balance was **$3 million** as of December 31, 2023[21](index=21&type=chunk)[22](index=22&type=chunk) [Note F – Goodwill and Other Intangibles](index=11&type=section&id=NOTE%20F%20%E2%80%93%20GOODWILL%20AND%20OTHER%20INTANGIBLES) No goodwill or indefinite-lived intangible asset impairments were identified during the quarter. The goodwill balance increased from $1,362 million to $1,396 million, primarily due to foreign currency translation adjustments. Total intangible assets were valued at $875 million Goodwill Progression by Segment (Q1 2024) | (In millions) | Sept 30, 2023 | Translation Adj. | Dec 31, 2023 | | :--- | :--- | :--- | :--- | | Life Sciences | $819 | $21 | $840 | | Personal Care | $122 | $2 | $124 | | Specialty Additives | $421 | $11 | $432 | | **Total** | **$1,362** | **$34** | **$1,396** | - Amortization expense for intangible assets was **$21 million** for the quarter. Estimated future amortization expense is **$79 million** for the remainder of 2024, and then decreasing annually to **$50 million** in 2028[50](index=50&type=chunk) [Note G – Debt and Other Financing Activities](index=12&type=section&id=NOTE%20G%20%E2%80%93%20DEBT%20AND%20OTHER%20FINANCING%20ACTIVITIES) Total debt stood at $1.34 billion as of December 31, 2023. The company terminated its 2018 Foreign Accounts Receivable Securitization Facility and entered a new three-year Foreign Accounts Receivable Sales Program in Europe with a limit of €125 million. Ashland remains in compliance with all debt covenants, with a consolidated net leverage ratio of 2.1, well below the 4.0 maximum - On October 19, 2023, Ashland entered into a new three-year Foreign Accounts Receivable Sales Program, allowing it to sell certain trade receivables up to a limit of **€125 million**. By quarter-end, **$102 million** in receivables had been sold under this new program[56](index=56&type=chunk)[58](index=58&type=chunk) - As of December 31, 2023, Ashland was in compliance with all debt covenants. The consolidated net leverage ratio was **2.1** (maximum permitted is **4.0**) and the interest coverage ratio was **7.6** (minimum required is **3.0**)[60](index=60&type=chunk)[228](index=228&type=chunk)[229](index=229&type=chunk) - Available borrowing capacity under the 2022 Credit Agreement was **$596 million** as of December 31, 2023[59](index=59&type=chunk) [Note I – Income Taxes](index=14&type=section&id=NOTE%20I%20%E2%80%93%20INCOME%20TAXES) The company reported an effective tax rate benefit of 600% for the quarter, a significant deviation from the prior year's 16% expense rate. This was primarily driven by the jurisdictional mix of income and a net $24 million favorable discrete tax item related to foreign tax reform activity. Unrecognized tax benefits increased slightly to $61 million - The effective tax rate was a **600% benefit** for Q1 2024, compared to a **16% expense** in Q1 2023. The significant change was due to jurisdictional income mix and a **$24 million** favorable discrete item from foreign tax reform[65](index=65&type=chunk)[66](index=66&type=chunk) Change in Unrecognized Tax Benefits | (In millions) | Amount | | :--- | :--- | | Balance at Oct 1, 2023 | $59 | | Increases for prior years | $3 | | Lapse of statute of limitations | ($1) | | **Balance at Dec 31, 2023** | **$61** | [Note K – Litigation, Claims and Contingencies](index=16&type=section&id=NOTE%20K%20%E2%80%93%20LITIGATION%2C%20CLAIMS%20AND%20CONTINGENCIES) Ashland faces significant liabilities from asbestos and environmental claims. As of December 31, 2023, total asbestos reserves were $457 million ($271 million for Ashland and $186 million for Hercules), with related insurance receivables of $139 million. Environmental remediation reserves stood at $207 million, with related insurance receivables of $16 million - Asbestos claims primarily stem from indemnification for the 1990 sale of Riley Stoker and the 2008 acquisition of Hercules[73](index=73&type=chunk) - The company estimates that total future asbestos litigation costs could range as high as **$422 million** for Ashland-related claims and **$288 million** for Hercules-related claims, on an inflated and undiscounted basis[92](index=92&type=chunk) Asbestos and Environmental Reserves (Dec 31, 2023) | (In millions) | Reserve Liability | Insurance Receivable | | :--- | :--- | :--- | | Ashland Asbestos | $271 | $93 | | Hercules Asbestos | $186 | $46 | | Environmental Remediation | $207 | $16 | [Note M – Equity Items](index=22&type=section&id=NOTE%20M%20%E2%80%93%20EQUITY%20ITEMS) In June 2023, the board authorized a new $1 billion evergreen stock repurchase program. During Q1 2024, the company repurchased 1.2 million shares for $100 million. A dividend of 38.5 cents per share was paid, an increase from 33.5 cents in the prior-year quarter - A new **$1 billion** evergreen stock repurchase program was authorized in June 2023. As of December 31, 2023, **$900 million** remained available[104](index=104&type=chunk) - In Q1 2024, Ashland repurchased **1.2 million shares** of common stock for a total of **$100 million** under a Rule 10b5-1 trading plan[105](index=105&type=chunk) - Dividends paid in Q1 2024 were **38.5 cents per share**, up from **33.5 cents per share** in Q1 2023[106](index=106&type=chunk) [Note P – Reportable Segment Information](index=26&type=section&id=NOTE%20P%20%E2%80%93%20REPORTABLE%20SEGMENT%20INFORMATION) The company operates through four reportable segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. For Q1 2024, Life Sciences was the largest contributor to sales ($200 million) and operating income ($32 million). Specialty Additives reported an operating loss of $32 million, heavily impacted by a $21 million accelerated depreciation charge Segment Financials (Q1 2024) | (In millions) | Sales | Operating Income (Loss) | EBITDA | | :--- | :--- | :--- | :--- | | Life Sciences | $200 | $32 | $48 | | Personal Care | $129 | $2 | $22 | | Specialty Additives | $122 | ($32) | $6 | | Intermediates | $33 | $7 | $10 | | Unallocated & other | - | ($27) | ($27) | | **Total** | **$473** | **($18)** | **$59** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=31&type=section&id=ITEM%202.%20MANAGEMENT'S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management attributes the 10% YoY sales decline to lower volumes across segments, partially offset by favorable pricing versus raw material costs. Adjusted EBITDA fell to $70 million from $108 million. The company is implementing portfolio optimization actions, including plant consolidations, expected to improve margins. For fiscal Q2 2024, Ashland forecasts sales of $565-$585 million and Adjusted EBITDA of $115-$125 million, anticipating a gradual recovery in the second half of the year [Business Overview](index=31&type=section&id=Business%20Overview) Ashland is a global additives and specialty ingredients company serving consumer and industrial markets. For the quarter, 66% of sales were generated outside North America. The Life Sciences segment was the largest contributor to sales at 42% Sales by Geography (Q1 2024 vs Q1 2023) | Region | % of Sales (2023) | % of Sales (2022) | | :--- | :--- | :--- | | North America | 34% | 30% | | Europe | 33% | 35% | | Asia Pacific | 24% | 25% | | Latin America & other | 9% | 10% | Sales by Reportable Segment (Q1 2024 vs Q1 2023) | Segment | % of Sales (2023) | % of Sales (2022) | | :--- | :--- | :--- | | Life Sciences | 42% | 40% | | Personal Care | 27% | 26% | | Specialty Additives | 26% | 27% | | Intermediates | 5% | 7% | [Results of Operations – Consolidated Review](index=33&type=section&id=Results%20of%20Operations%20%E2%80%93%20Consolidated%20Review) Consolidated sales decreased by $52 million (9.9%) YoY, primarily due to a $51 million negative impact from lower volume. Gross profit margin fell to 20.7% from 31.4%, driven by higher unit manufacturing costs from decreased plant loading, including a $21 million accelerated depreciation charge. Selling, general, and administrative expenses decreased by $10 million to $83 million Reconciliation of Change in Sales (Q1 2024 vs Q1 2023) | (In millions) | Change | | :--- | :--- | | Volume | ($51) | | Pricing | ($6) | | Divestiture | ($1) | | Foreign currency exchange | $6 | | **Total Change in Sales** | **($52)** | - Cost of sales increased by **$15 million**, primarily due to higher operating costs from decreased plant loading, which included **$21 million** in accelerated depreciation for product line optimization activities[150](index=150&type=chunk) - Net interest and other income increased by **$10 million**, mainly due to higher income from restricted investments, which included realized gains of **$31 million** in the current quarter versus **$21 million** in the prior-year quarter[157](index=157&type=chunk) [Use of Non-GAAP Financial Measures](index=38&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) The company uses non-GAAP measures like EBITDA and Adjusted EBITDA to assess performance. For Q1 2024, Adjusted EBITDA was $70 million, down from $108 million YoY. Key adjustments to reconcile net income to Adjusted EBITDA included $21 million in accelerated depreciation, $5 million for the Argentina currency devaluation, and a $31 million unrealized gain on securities Reconciliation of Net Income to Adjusted EBITDA | (In millions) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Net Income** | **$26** | **$40** | | Income tax expense (benefit) | ($24) | $8 | | Net interest and other income | ($24) | ($14) | | Depreciation and amortization | $56 | $59 | | **EBITDA** | **$34** | **$93** | | Loss from discontinued operations | $2 | $2 | | Key items (Restructuring, impairments, etc.) | $34 | $13 | | **Adjusted EBITDA** | **$70** | **$108** | Adjusted Diluted EPS Reconciliation | Per Share Data | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Diluted EPS from continuing operations | $0.54 | $0.76 | | Total key items adjustment | ($0.42) | ($0.12) | | **Adjusted diluted EPS (non-GAAP)** | **$0.12** | **$0.64** | | Amortization expense adjustment (net of tax) | $0.33 | $0.33 | | **Adjusted diluted EPS excluding intangibles (non-GAAP)** | **$0.45** | **$0.97** | [Results of Operations – Reportable Segment Review](index=43&type=section&id=Results%20of%20Operations%20%E2%80%93%20Reportable%20Segment%20Review) All segments experienced sales and EBITDA declines in Q1 2024. Life Sciences sales fell 3% to $200 million. Personal Care sales dropped 7% to $129 million. Specialty Additives sales decreased 15% to $122 million, with its operating income swinging to a $32 million loss due to restructuring. Intermediates sales fell 39% to $33 million due to lower volume and pricing - **Life Sciences:** Adjusted EBITDA decreased by **$4 million** to **$48 million**, driven by lower volume and higher costs, partially offset by favorable pricing[193](index=193&type=chunk) - **Personal Care:** EBITDA decreased by **$10 million** to **$22 million**, primarily due to higher costs and lower volume[200](index=200&type=chunk) - **Specialty Additives:** Adjusted EBITDA fell by **$17 million** to **$6 million**, impacted by higher costs (including **$21 million** in accelerated depreciation) and lower volume[206](index=206&type=chunk) - **Intermediates:** EBITDA decreased by **$13 million** to **$10 million**, due to lower volume, unfavorable price/mix, and higher costs[212](index=212&type=chunk) [Financial Position](index=50&type=section&id=Financial%20Position) Ashland's liquidity remains strong with $1.04 billion in available liquidity as of December 31, 2023, including $440 million in cash and $596 million in revolving credit capacity. Ongoing free cash flow was $66 million for the quarter, a significant improvement from a $21 million outflow in the prior year, driven by better working capital management. Total debt was $1.34 billion, and the company was in compliance with all debt covenants Free Cash Flow Calculation | (In millions) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Cash from operating activities (continuing) | $201 | ($29) | | less: Additions to property, plant and equipment | ($36) | ($23) | | **Free cash flow** | **$165** | **($52)** | | Adjustments for A/R programs & one-time payments | ($91) | $31 | | **Ongoing free cash flow** | **$66** | **($21)** | - Total available liquidity was **$1,036 million** at quarter-end, composed of cash and the revolving credit facility. The company also held **$392 million** in restricted investments for future asbestos and environmental payments[224](index=224&type=chunk) - Capital expenditures were **$36 million** for the quarter, up from **$23 million** in the prior-year period[234](index=234&type=chunk) [Outlook](index=53&type=section&id=OUTLOOK) Ashland anticipates a potential recovery with continued momentum into the second half of the fiscal year, noting sequential demand improvement in January and February. The company is continuing its portfolio optimization, including the closure of CMC production in Hopewell, VA. For fiscal 2024, Ashland provides guidance for sales between $2.15 billion and $2.25 billion and Adjusted EBITDA between $460 million and $500 million Fiscal 2024 Guidance | Metric | Q2 2024 Forecast | Full Year 2024 Forecast | | :--- | :--- | :--- | | Sales | $565M - $585M | $2.15B - $2.25B | | Adjusted EBITDA | $115M - $125M | $460M - $500M | - Portfolio optimization actions continue, including the consolidation of carboxymethylcellulose (CMC) production, which will result in the closure of the Hopewell, Virginia facility in Q2 2024[236](index=236&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=55&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company states that its market risk exposure as of December 31, 2023, is generally consistent with the exposures presented in its Annual Report on Form 10-K for the fiscal year ended September 30, 2023 - There were no material changes to market risk exposures during the quarter[238](index=238&type=chunk) [Item 4. Controls and Procedures](index=55&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Based on an evaluation as of December 31, 2023, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective. There were no significant changes in internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of December 31, 2023[239](index=239&type=chunk) - No significant changes to internal control over financial reporting occurred during the quarter[240](index=240&type=chunk) PART II – OTHER INFORMATION [Item 1. Legal Proceedings](index=56&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) Ashland remains subject to material legal proceedings, primarily concerning asbestos-related personal injury claims and environmental remediation. Asbestos liabilities stem from the past operations of Riley Stoker and Hercules. Environmental proceedings involve being named a Potentially Responsible Party (PRP) at 55 Superfund or similar sites - The company is a defendant in asbestos-related lawsuits stemming from indemnification obligations for the former subsidiary Riley Stoker and from the acquisition of Hercules LLC[243](index=243&type=chunk) - As of December 31, 2023, Ashland has been identified as a Potentially Responsible Party (PRP) for environmental investigation and/or cleanup at **55 sites** under CERCLA or similar state laws[245](index=245&type=chunk) [Item 1A. Risk Factors](index=58&type=section&id=ITEM%201A.%20RISK%20FACTORS) There were no material changes from the risk factors previously disclosed in Ashland's Annual Report on Form 10-K for the fiscal year ended September 30, 2023 - No material changes to risk factors were reported for the period[248](index=248&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=58&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) During the first quarter of fiscal 2024, Ashland repurchased a total of 1,238,212 shares of its common stock. These purchases were made under the new $1 billion evergreen share repurchase program authorized in June 2023. As of December 31, 2023, $900 million remained available under this authorization Share Repurchase Activity (Q1 2024) | Period | Total Shares Purchased | Average Price Paid Per Share | | :--- | :--- | :--- | | Oct 2023 | 0 | N/A | | Nov 2023 | 666,315 | $78.09 | | Dec 2023 | 571,897 | $83.87 | | **Total** | **1,238,212** | **N/A** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission file number 333-211719 ASHLAND INC. Delaware (State or other jurisdiction of incorporation or organization) 81-2587835 (I.R.S. Employer I ...

Ashland Inc. (NYSE:ASH) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Seth Mrozek - Director, Investor Relations Guillermo Novo - Chair and Chief Executive Officer Kevin Willis - Senior Vice President and Chief Financial Officer Conference Call Participants David Begleiter - Deutsche Bank John McNulty - BMO Capital Markets Lucas Spector - UBS Group AG John Roberts - Mizuho Securities USA LLC Jeff Zekauskas - JPMorgan Chase & Co. Mike Harrison - Seaport Research Partners L ...

earnings conference call third-quarter fiscal 2023 July 26, 2023 I 9:00 am ET Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Actof1934,asamended. Ashlandhasidentifiedsomeoftheseforward-lookingstatementswithwordssuchas“anticipates,”“believes,”“expects,”“estimates,” “islikely,”“predicts,”“projects,”“forecasts,”“objectives,”“may,”“will,”“should,”“plans”and“int ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 ASHLAND INC. (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Number ...